Immunoprotective Leishmania major synthetic T cell epitopes by unknown
BriefDefinitive Report
Immunoprotective Zeishmania major Synthetic
T Cell Epitopes
By Armando Jardim,* James Alexander,# Hung Sia Teh,§
Dawei Ou,§ and Robert W. Olafson*
From the 'Department ofBiochemistry and Microbiology, University of Victoria, Victoria, BC,
Canada, V8W 2Y2; the DDepartment ofBioscience and Technology, Immunology Division,
University of Strathclyde, The Todd Centre, Glasgow, Scotland, G4 ONR; and the §Department
of Microbiology, University of British Columbia, Vancouver, BC, Canada, V6T IW5
Summary
Using the predictive algorithm of Rothbard and Taylor (1988. EMBOJ. 7:93) and the primary
structure of gp63 (Button, L., and M.R. McMaster. 1988. J. Exp. Med. 167:724; Miller, R.A.,
S.G. Reed, and M. Parsons. 1990. Mol. Biochem. Parasitol. 39:267) we have been able to delineate
the structures of a number of gp63 T-cell epitopes which stimulate the proliferation of CD4'
cells. One of these synthetic antigens, inoculated subcutaneously with adjuvant, was shown to
specifically induce proliferation of the Thl subset and provided immunoprotection against two
species of Leishmania parasites.
R
ecent studies by Russell and Alexander have demonstrated
that immunization ofmice with the major cell surface
glycoprotein gp63, results in cell-mediated immunity and pro-
tection from Leishmania mexicana infections (1). These findings
suggested the possibility that the structures of the gp63 T
cell epitopes might be predicted and chemically synthesized
using the known Leishmania major primary structure (2) and
the predictive algorithm proposed by Rothbard and Taylor
(3). We report here that three synthetic T cell epitopes of
the immunoprotective gp63 molecule stimulate proliferation
of murine CD4+ cells and that one specifically stimulates
Thl cells, the subset proposed to be responsible for im-
munoprotection in mice (4). The latter epitope was further
shown to protect vaccinated mice from cutaneous leishmaniasis.
Materials and Methods
Animals.
￿
Mice were purchased from either The Jackson Labo-
ratory (Bar Harbor, ME) or from the Charles River Breeding labora-
tories (St. Constant, Quebec) and used at 8-10 wk of age. BALB/c
mice for vaccine trials were bred in-house.
Synthetic Rptides.
￿
The following peptides were synthesized using
Merrifield solid-phase methodologies on an Applied Biosystems Inc.
(Foster City, CA) Model 430A peptide synthesizer and com-
positions confirmed by amino acid analysis: PTl, VRDVN-
WGALRIAVS; PT2, LTNEKRDILVKHLIP; PT3, YDQLV
TRVVTHEMAHA; PT4, TRVVTHEMAHALGFSG; PT6,
PFNVFSDAARCIDGAF; PT7, AARCIDGAFRPKATDG; PT8,
RPKATDGIVKSYAGLC. The peptides represent gp63 residues
1-13,48-61,154-168,158-173,378-393,385-401, and 394-409,
respectively.
TCell Proliferation Assays.
￿
Three animals were inoculated sub-
cutaneously with 50 p,g of peptide emulsified in 100 141 of CFA.
Lymph nodes were removed after 9 d and 5 x 105 cells incubated
for 3 d with synthetic peptides followed by further incubation for
20 h with 1 uCi ['H]TdR. Controls show the incorporation of
[3H]TdR into unprimed lymph node cells incubated with peptides
or 2 fig/ml Con A, as well as the incorporation into primed lym-
phocytes in the absence ofchallenge peptides. Control B cell prolifer-
ations used 20,ug/ml ofEscherichia coli LPS. Lymphocyte stimula-
tion was plotted as the average counts per minute (cpm) oftriplicate
experimental cultures minus the average of the relevant triplicate
control values. Each of the proliferation experiments was replicated
at least twice.
Complement-mediated Cell Lysis.
￿
Lysis was carried out using 5
x 105 lymph node cells incubated with either alloanti-Thy-1 an-
tisera, anti-L3T4' or anti-Lyt-2.2' mAbs (Cedarlane Laboratories
Ltd., Hornby, Ontario) for 60 min at 4°C, followed by addition
of 10% rabbit complement for 60 min at 37°C.
Lymphokine Determinations.
￿
11,2 and 11,4 were assayed using
the IL2- and 114-dependent CTLLr2 cell line (ATCC TIB 214).
Specific neutralization was achieved with an anti-11,2 antibody, S4B6
(17), or with the anti-IL-4 antibody 11BIl (ATCC HB). 11,3 was
determined using the IL3-dependent cell line DA-1. Results were
expressed as units oflymphokineextrapolated from standard recom-
binant interleukin curves.
Immunoprotection Trial.
￿
Four groups of eight female BALB/c
mice were used in this study. Each group was injected subcutane-
ously with 100 hg of test peptide in a temperature-dependent sol
gel transition adjuvant, 8% Poloxamer 407 (BASF, Wayandotte,
Ludwigshaven, FRG) with exception of the control group, which
received only adjuvant. After 6 wk the mice were inoculated sub-
cutaneously in the hind quarters with 2 x 10" stationary phase
L. majorpromastigotes. A similar study used L. mexicana promas-
tigotes and CBA mice. Progress ofdisease was monitored by mea-
surement of lesion diameter beginning at 4 wk after inoculation.
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The primary structure of L. major gp63, as described by
Button and McMaster (2) and corrected by Miller et al. (5),
was used along with the predictive algorithm of Rothbard
and Taylor (3) to select seven peptide sequences as potential
T cell epitopes (PT1-4 and PT6-8). The ability of these pep-
tides to stimulate lymphocyte proliferation was tested by im-
munization of mice, followed by in vitro challenge of iso-
lated lymph node cells with the test peptides. Fig. 1 shows
the dose-response curves after challenge ofprimed lymph node
cells with the immunizing peptides. Threepeptides were found
to be stimulatory. The overlapping peptides PT3 and PT4,
which cover a highly conserved region believed to be respon-
sible for zinc binding (6, 7), stimulated proliferation in cells
derived from BALB/c (H-2d), A/J (H-2'), and CBA (H-2k)
mice but not in C57BL/6 (H-2b) lymphocytes. Peptide PT6
was pan-specific for this collection of mouse haplotypes,
stimulating lymphocytes from all strains. Verification that
j3H]TdR incorporation was associated with T cell prolifer-
ation was provided by T cell-specific depletion using anti-
Thy-1 antisera (data not shown) or anti-L3T4+ mAb and
complement (Fig. 2). While only data for the peptide PT6
are shown, similar proliferation data were obtained for pep-
tidesPT3 and PT4 and in experiments with lymphocytes from
the other responding mouse strains. These data show that
the proliferating cells are primarily of the CD4+ subset. Evi-
dence was also obtained that the B cell population was
unaffected by the depletion procedure by using the B cell
mitogen LPS (Fig. 2).
Recent findings have suggested that proliferation of either
the CD4 * Thl or Th2 subsets determines whether an im-
munoprotective or disease exacerbating condition is found
7ó- -l'O, ' o .`6=10° " 7b-, ' io ' 7'o'
Peptide Concentration X 3.73 nanomolar
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Figure 1.
￿
T cell proliferation dose-response curves for seven
L. major gp63 synthetic peptides screened against four mouse strains
with differing MHC haplotypes. Data represent averages of triplicate
proliferation experiments after subtraction of average control prolifera-
tions. The average control values were: C57BL/6, 6.8 x 103 cpm;
BALB/c, 11.6 x 103 cpm; CBA, 21.8 x 103 cpm, and A/J, 8.4 x
103 cpm. PT1 (á), PT2 (A), PT3 (O), PT4 ("), PT6 (M), PT7
(p), PTS (C).
0 n
o O
180
c -120
E E a
60
-Z
A B C D E F
z KALB/
ó 130-
110,
90~
Immunoprotective Leishmania Synthetic T Cell Epitopes
z
v
L7
84-
E
220
F
C57BL/6
11111 r--, <1-
A B C D E F
Figure 2.
￿
Effect of anti-L3T4* (CD4+) and anti-Lyt-2.2* (CD8 *)
mAbs and rabbit complement on PT6 stimulation of primed lympho-
cytes. (A and B) Lymph node cells from immunized mice incubated
with anti-L3T4*, or anti-Lyt-2.2+ mAb and rabbit complement fol-
lowed by PT6 (156 p.M). (C) Complement alone followed by peptide.
(D) No additions. (E) LPS-induced proliferation. (F) LPS proliferation
after exposure to anti-L3T4+ antibody and complement.
after infection with Leishmania major (4). A study of lym-
phokine production, afterchallenge oflymph node cellswith
the stimulatory peptides, showed that only PT3 was capable
of stimulating 11,2 (Table 1) and that none of the epitopes
produced measurable IL4. It could be concluded that under
the immunization protocol used, PT3 specifically induced
proliferation of the CD4+ Thl subset (8). These findings,
together with the fact that gp63 was known to elicit protec-
tive cell-mediated immunity in mice (1), strongly supported
the candidacy of the PT3 epitope as a potential vaccine for
cutaneous leishmaniasis.
Results ofimmunoprotection experiments using these syn-
thetic epitopes showed that a molecularly defined vaccine was
Table 1.
￿
Lymphokine Production after Stimulation of T Cells
from BALBlc and CBA mice with Synthetic gp63 Peptides
Lymphokine*
IL-2 IL-3 IL-4
Challenge
peptide
￿
BALB/c CBA BALB/c CBA BALB/c CBA
IJ/mi
PT3 0.8 1.9 3.8 ND 0 0
PT4 0 0 0.3 ND 0 0
PT6 0 0 7.0 ND 0 0
No peptide
￿
0
￿
0
￿
0
￿
0
￿
0
￿
0
Zero values indicate no detectable lymphokine.
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￿
Development of L . major infection in groups of eight
BALB/c mice after immunization with synthetic peptides . Lesion di-
ameters are shown above each bar along with the SEM. Controls
receiving adjuvant only (hatched bar); PT3 (solid bar) ; PT4 (open bar) ;
PT6 (shaded bar) .
a strong possibility. BALB/c mice were injected with a single
dose ofeither peptide PT3, PT4, orPT6 in adjuvant, or with
adjuvant alone, and after a 6 wk rest were infected with 2
x 10° stationary phase . L. major promastigotes. Fig 3 shows
results of the first study using the adjuvant Poloxamer 407 .
Lesion development was evident at 4 wk in control animals,
as well as in animals inoculated with PT4 and PT6 but not
in the group immunized with PT3 . At 6 wk the number
of infected animals in previously infected groups increased,
along with the average lesion size, while no evidence of in-
fection could be found in the group immunized with PT3
plus adjuvant . Not until 2 mo after inoculation was there
evidence of lesion development in the latter group. This ap-
peared to be the end of a period of premunition induced by
the single subcutaneous injection of antigen . A second ex-
periment, using the same protocol but with a slightly higher
adjuvant concentration (12.5%), provided further verification
of the immunoprotective capacity ofPT3 . Not only was this
peptide once again shown to limit the disease, but half the
animals vaccinated with PT3 cured ofdisease 12-16 wk after
inoculation with parasites. Results usingLeishmania mexicana
and the previous protocol were even more convincing, with
complete lack of disease in the vaccinated group 3 mo after
parasite challenge.
That these findings were not entirely related to the Polox-
amer 407 adjuvant was shown by conducting anotherL . major
experiment but replacing Poloxamer with CFA . No sign of
disease was found in vaccinated animals 5 wk after parasite
inoculation, while all controls showed lesion development .
Nonetheless an interesting result from the second L. major
experiment with Poloxamer indicated that the use of adju-
vant was an important determinant in the outcome of these
subcutaneous vaccinations. When PT3 was injected in the
absence of adjuvant, an exacerbation in lesion growth was
observed (data not shown) . This result mimicked a previ-
ously described disease exacerbation produced in BALB/c mice
after subcutaneous vaccination with irradiated L. major
promastigotes (9, 10) . A possible explanation for these results
has recently been proposed suggesting that adjuvant could
affect the physiological state ofAPCs, stimulating produc-
tion of costimulatory factors appropriate for Thl, rather than
Th2 cell proliferation (11) .
While long-term immunity was not attained with a single
injection, these results are very promising and experiments
to further characterize the immunoprotective utility of the
synthetic peptides are now in progress . It should be feasible
to assess whether the same epitope can induce protection or
exacerbation dependent upon the route or mode of adminis-
tration, and conversely, whether several types ofepitopes can
exist within the gp63 structure. Indeed preliminary evidence
has indicated that using the Poloxamer adjuvant both forms
ofepitope are found in gp63, arguing against the general utility
of large, undefined, recombinant antigens. Experimentation
can now proceed with single epitopes, rather than complex
structures containing both an array of undefined T cell epi-
topes as well as oligosaccharides. The findings reported here
show that a molecularly defined approach to a solution of
these problems is not only feasible but critical for the devel-
opment of vaccines against cutaneous leishmaniasis.
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